Immugenia is an early stage immuno-oncology company developing a novel approach to CAR therapy by engineering hematopoietic stem cells to treat cancer and prevent relapses. Our proprietary technology allows for the CAR to be expressed selectively in T and NK cells in order to leverage their synergistic activity against cancer.

To enhance accessibility to CAR therapy, Immugenia is advancing research to administer CAR therapy directly in vivo, thus bypassing the need for ex vivo cell modifications. This approach combines our proprietary promoter technology, which allows CAR expression to be selective to T and NK cells, with lentiviral particles specifically designed to target immune cells.

In this process, hematopoietic stem cells (HSCs), T cells, or NK cells are engineered with a CAR whose expression is regulated by our proprietary promoter(s). This targeted expression is confined to the T and NK cell lineages, allowing for continuous replenishment of CAR-T and CAR-NK cells when HSCs are engineered. Additionally, this method incorporates a safety feature that ensures CAR expression is restricted to the intended immune cells, minimizing off-target effects.